|
Mitomycin is one of the older chemotherapy drugs, which
has been around and in use for decades. It is an active medicine against
many cancers. Mitomycin is a purple color powder, or liquid, and is given by
intravenous route only. (http://www.tirgan.com/mitomycin.htm)
Mitomycin is chemotherapy
that is given as a treatment for some types of cancer (http://www.cancerbacup.org.uk/info/mitomycin.htm)
COMMON TRADE NAME(S):
Mutamycin® (http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexALPro/Mitomycin.htm)
|
The Mitomycin formula
----------------------------------------------------
Mitomycin biosynthesis (from
http://www.cbs.umn.edu/asirc/biosynthetic_pathways/)
|
- Haskell CM, ed. Cancer treatment, 3rd ed.
Philadelphia: WB Saunders Co, 1990.
- Dorr RT, Fritz WL, eds. Cancer
chemotherapy handbook. New York: Elsevier Science Publishing Co Inc,
1980:548-55.
- Krogh CME, ed. Compendium of
pharmaceuticals and specialties, 28th ed. Ottawa: Canadian Pharmaceutical
Association, 1993:761-2.
- Kastrup EK, et al, eds. Facts and
comparisons: Loose-leaf information service. St. Louis: JB Lippincott Co,
1993:664.
- Wiebe VJ, et al. Clinical pharmacokinetics
of drugs used in the treatment of breast cancer. Clin Pharmacokin
1988;15:80-93.
- Torti FM, et al. The biology and treatment
of superficial bladder cancer. J Clin Onc 1984;2:505-31.
- McEvoy GK, ed. American hospital formulary
service: Drug information 1994. Bethesda: American Society of Hospital
Pharmacists, 1994:669
- Bennett WM. Guide to drug dosage in renal
failure. Clin Pharmacokin 1988;15:326-54.
- Pinedo HM, Chabner BA, eds. Cancer
chemotherapy/7: The EORTC Cancer Chemotherapy Annual. New York: Elsevier
Science Publishing Co Inc, 1985:83-90.
- Crooke ST, et al. Phase I study of oral
Mitomycin C. Cancer Treat Rep 1976;60:1633-6.
- Vermeij J, den Hartigh J, Stuurman M, et
al. Relationship between clinical parameters and pharmacokinetics of
mitomycin. J Cancer Res Clin Oncol 1987;113:91-4.
- Knoben JE, Anderson PO, eds. Handbook of
clinical drug data, 6th ed. Hamilton: Drug Intelligence Publications Inc,
1988.
- Dorr RT, Von Hoff DD. Cancer chemotherapy
handbook, 2nd ed. Norwalk: Appleton & Lange, 1994:717-26.
- Dorr RT. New findings in the
pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C.
Semin Oncol 1988;15(No 3 Suppl 4):32-41.
- Drugs of choice for cancer chemotherapy.
Med Lett Drugs Ther 1993;35:43-50.
- Buzdar AU, Legha SS, Tashima CK.
Adriamycin and mitomycin C: Possible synergistic cardiotoxocity. Cancer
Treat Rep 1978;62:1005-6.
- Riggs CE. Antitumor antibiotics and
related compounds. In: Perry MC, ed. The chemotherapy source book.
Baltimore: Williams & Wilkins, 1992:337-40.
- Leudke D, McLaughlin TT, Doughaday C, et
al. Mitomycin C and vindesine associated pulmonary toxicity with variable
clinical expression. Cancer 1985;55:542-5.
- Bristol Laboratories of Canada. Mutamycin
package insert. Belleville, Ontario.
- Trissel LA. Handbook on injectable drugs,
7th ed. Bethesda: American Society of Hospital Pharmacists, 1992.
- King JC. Guide to parenteral admixtures.
St. Louis: KabiVitrum Inc, 1992.
- Trissel LA, Tramonte SM, Grilley BJ.
Visual compatability of ondansetron hydrochloride with selected drugs
during simulated Y-site injection. Am J Hosp Pharm 1991;48:988-92.
- Issell BF, et al. Mitomycin C intravesical
therapy in noninvasive bladder cancer after failure on thiotepa. Cancer
1984;53:1025-28.
- USP DI Volume I: Drug information for the
health care professional, 14th ed. Rockville: United States Pharmacopeial
Convention Inc, 1994:1934-7.
- USP DI Volume II: Advice for the patient:
Drug information in lay language, 14th ed. Rockville: United States
Pharmacopeial Convention Inc, 1994:932-4.
- Au JL-S, Badalament RA,
Wientjes MG, et al. Methods to Improve Efficacy of Intravesical Mitomycin
C: Results of a Randomized Phase III Trial. JNCI Cancer Spectrum
2001;93(8):597-604.
|
